RecruitingNot ApplicableNCT06442592

Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects

CATAMARAN - Pediatrics : Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects


Sponsor

Nantes University Hospital

Enrollment

1,206 participants

Start Date

Jul 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The leading cause of birth defects, Congenital Heart Defects (CHD) affect 12 million people worldwide and 41,000 newborns/year in Europe. It's a major cause of life-long morbidity and mortality, and a crucial public health issue. More than 50% of childs born with critical CHD will develop Neurodevelopmental Disorders (NDs), requiring specific care and impairing quality of life. NDs corresponds to early and lasting disturbances in cognitive, affective and behavioral development, linked to abnormalities in brain development. They are heterogeneous, affecting language, learning, motor skills, intellectual efficiency, social cognition, attention, memory and executive functions, and are associated with psychosocial difficulties (adaptive behavior, social interactions). This hidden handicap is the main long-term sequels of CHD, even before cardiovascular sequels, in individuals who often underwent multiple heart operations in early childhood. NDs concern not only complex CHD, but also simple CHD repaired in childhood and considered cured. The origin of TND associated with CHD is largely unknown. To date, few genetic or environmental causes have been clearly identified, but recent work has suggested that a common origin may link cardiac malformation and neurodevelopmental abnormality. The CATAMARAN - Pediatrics project is designed to detect potential neurodevelopmental delays associated with CHD as early as age 3, and to identify individual susceptibility factors involved in the occurrence of NDs in CHD children.


Eligibility

Min Age: 3 YearsMax Age: 11 Years

Inclusion Criteria6

  • Child (aged 3 to 11) with critical MCC operated on for heart surgery during the first three months of life
  • Parents and child affiliated with or benefiting from a social security or similar scheme
  • Parents' and child's good understanding of the French language
  • Free, informed and written consent of both parents for themselves and for the child
  • Free, informed and written consent of the child aged 6 and over
  • Biological parents

Exclusion Criteria2

  • Genetic anomaly or malformative syndrome associated with neurodevelopmental abnormalities, identified prior to inclusion
  • Neurodevelopmental assessment not practicable

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sampling

An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.

DIAGNOSTIC_TESTAssessment of neurodevelopment (CA)

The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.

DIAGNOSTIC_TESTAssessment of neurodevelopment (Nantes)

The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.

OTHERAssessment of the parental stress

Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.


Locations(5)

Chu Brest

Brest, Brittany Region, France

CHU Rennes

Rennes, Brittany Region, France

CHU Nantes

Nantes, Loire-Atlantique, France

CHU Angers

Angers, Maine-et-Loire, France

CHU Tours

Tours, Val de Loire, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06442592


Related Trials